Share on StockTwits
 

Merck & Co (NYSE:MRK) is set to issue its quarterly earnings data on Wednesday, February 5th. Individual interested in participating in the company’s earnings conference call can do so using this link.

Merck & Co (NYSE:MRK) opened at 52.08 on Tuesday. Merck & Co has a 52 week low of $40.83 and a 52 week high of $54.10. The stock has a 50-day moving average of $50.66 and a 200-day moving average of $48.45. The company has a market cap of $152.2 billion and a price-to-earnings ratio of 35.60.

A number of research firms have recently commented on MRK. Analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Monday. On a related note, analysts at Morgan Stanley upgraded shares of Merck & Co from an “equal weight” rating to an “overweight” rating in a research note to investors on Monday, January 27th. They now have a $60.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. Merck & Co has a consensus rating of “Hold” and an average price target of $53.81.

Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.